The Expanding Role of AI in Diagnostics
The diagnostics sector is experiencing an AI-driven transformation across three fronts: companion diagnostics (CDx) development using ML-based biomarker discovery, digital pathology with computer vision, and emerging digital health applications using wearable sensor data.
Companion Diagnostics
ML algorithms identify multi-analyte signatures that predict treatment response more accurately than single-biomarker tests. The regulatory pathway through IVDR in the EU and Swissmedic in Switzerland requires specific validation evidence for AI-based CDx.
Digital Pathology
Computer vision models achieve 95%+ concordance with expert pathologists for tumor grading while reducing review time by 40%. CE-IVD marking pathways enable EU deployment.
Digital Health Monitoring
AI applied to continuous wearable data — heart rate variability, activity patterns, sleep quality — enables early detection of disease deterioration and adverse events. This is particularly valuable for decentralized clinical trials and post-market surveillance.
- 30-50% improvement in diagnostic sensitivity for rare conditions
- Earlier detection of treatment-related adverse events
- Reduced healthcare costs through precision diagnostics